Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhejiang Univ. of Technology cathepsin L (CTSL) compound B5
- Development stage
- Unknown
- Lead developer
- Zhejiang University of Technology
01
Overview
Zhejiang Univ. of Technology cathepsin L (CTSL) compound B5: sourced facts only. name: "In addition, B5 effectively inhibited CTSL enzymatic activity, with an IC50 value of 5.52 μM." [PMID:41653775]; target: "In addition, B5 effectively inhibited CTSL enzymatic activity, with an IC50 value of 5.52 μM." [PMID:41653775]; developer: "College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, PR China." [PMID:41653775]; stage: "In LPS-induced ALI mouse model, treatment with B5 (20 mg/kg) significantly reduced inflammatory cell infiltration into lung tissue, thereby markedly alleviating lung injury." [PMID:41653775]
02
Targets
pro-CTSL (Cathepsin L)
Beyond the preview
Go deeper on Zhejiang Univ. of Technology cathepsin L (CTSL) compound B5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Univ. of Technology cathepsin L (CTSL) compound B5.